New shot could shield breast cancer patients from dangerous chemo side effect
NCT ID NCT06711523
First seen Jan 08, 2026 · Last updated May 01, 2026 · Updated 13 times
Summary
This study tests a new medication (PEG-G-CSF) to prevent neutropenia, a condition where white blood cell counts drop dangerously low after chemotherapy. It involves 250 female breast cancer patients aged 18 to 75 who are starting certain chemotherapy regimens. The goal is to see if the new drug works as well as an existing approved drug (Neulasta) in preventing severe neutropenia and its complications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST NEOPLASM FEMALE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
Conditions
Explore the condition pages connected to this study.